JOHNS HOPKINS UNIVERSITY

🇳🇦Namibia

Country: 🇳🇦Namibia

Ownership: -

Established: 1876-01-01

Employees: 19.4K

Market Cap: -

Website: https://www.jhu.edu/

Clinical Trials

Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis
Vitamin D Deficiency

Interventions: Drug: Cholecalciferol

First Posted Date: 2009-12-03

Last Posted Date: 2013-02-06

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 40

Registration Number: NCT01024777

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

Phase 4

Completed

Conditions: Tourette Syndrome

Interventions: Drug: Placebo
Drug: Riluzole
Drug: D-serine

First Posted Date: 2009-11-23

Last Posted Date: 2018-01-30

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 39

Registration Number: NCT01018056

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Dietary Supplement: KetoCal

First Posted Date: 2009-11-19

Last Posted Date: 2015-04-01

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1

Registration Number: NCT01016522

Locations: 🇺🇸
Johns Hopkins ALS Clinic, Baltimore, Maryland, United States

Doxycycline Outcomes in Lupus Erythematosus

Phase 4

Withdrawn

Conditions: Cardiovascular Disease

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2009-11-16

Last Posted Date: 2012-03-30

Lead Sponsor: Johns Hopkins University

Registration Number: NCT01014260

Locations: 🇺🇸
Johns Hopkins University SOM. 1830 East Monument St, Ste 7500, Baltimore, Maryland, United States

Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Phase 4

Terminated

Conditions: Patients With Nasal Polyps

Interventions: Other: placebo
Drug: fluticasone furoate

First Posted Date: 2009-11-16

Last Posted Date: 2017-09-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 7

Registration Number: NCT01013701

Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience

Not Applicable

Completed

Conditions: Cystic Fibrosis

Interventions: Other: Cystic Fibrosis Education
Behavioral: Motivational Interviewing

First Posted Date: 2009-11-16

Last Posted Date: 2015-03-31

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 128

Registration Number: NCT01013896

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence

Phase 1

Terminated

Conditions: Bladder Exstrophy
Urinary Incontinence

Interventions: Drug: MDC

First Posted Date: 2009-11-11

Last Posted Date: 2020-01-28

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 2

Registration Number: NCT01011777

Locations: 🇺🇸
Brady Urological Institute. Johns Hopkins University, Baltimore, Maryland, United States

The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

Phase 2

Completed

Conditions: Cat Allergy

Interventions: Drug: Placebo
Drug: Omalizumab

First Posted Date: 2009-10-28

Last Posted Date: 2014-04-07

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 19

Registration Number: NCT01003301

Locations: 🇺🇸
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States

Human Psychopharmacology of Salvinorin A

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Salvinorin A

First Posted Date: 2009-10-16

Last Posted Date: 2014-03-24

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 14

Registration Number: NCT00996411

Locations: 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
🇺🇸
Behavioral Pharmacology Research Unit, Johnson Hopkins Univ. School of Med., Baltimore, Maryland, United States

The Effects of Broccoli Sprout Extract on Obstructive Lung Disease

Not Applicable

Completed

Conditions: Asthma
COPD

Interventions: Drug: broccoli sprout extract

First Posted Date: 2009-10-14

Last Posted Date: 2017-01-27

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 51

Registration Number: NCT00994604

Locations: 🇺🇸
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy